RecruitingPhase 2NCT07104565

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Sponsor

Incyte Corporation

Enrollment

56 participants

Start Date

Dec 29, 2025

Study Type

INTERVENTIONAL

Conditions

Immune Thrombocytopenia

Summary

This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INCA000585 for people with immune thrombocytopenia. The study is currently recruiting participants at 40 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCA000585

Tafasitamab will be administered intravenously at protocol defined timepoints.

Locations(40)

Palo Verde Cancer Specialists Palo Verde Hematology Oncology, Ltd Glendale

Glendale, Arizona, United States

Usc Norris Comprehensive Cancer Center

Los Angeles, California, United States

Rocky Mountain Cancer Centers

Lone Tree, Colorado, United States

Yale University School of Medicine

New Haven, Connecticut, United States

Gnp Research

Cooper City, Florida, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Montefiore Medical Center

The Bronx, New York, United States

Inova Schar Cancer Institute

Fairfax, Virginia, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

Versiti Bloodcenter of Wisconsin Bcw Milwaukee

Milwaukee, Wisconsin, United States

St Vincent'S Hospital Sydney

Darlinghurst, New South Wales, Australia

Townsville University Hospital

Douglas, Queensland, Australia

Princess Alexandra Hospital Australia

Woolloongabba, Queensland, Australia

Box Hill Hospital

Box Hill, Victoria, Australia

Monash Medical Centre Clayton

Clayton, Victoria, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Chu Angers - Hôpital Hôtel Dieu

Angers, France

Chu Caen - Hôpital de La Côte de Nacre

Caen, France

Hôpital Henri Mondor

Créteil, France

Chu Dijon - Hopital Du Bocage

Dijon, France

Chu Bordeaux - Hôpital Haut-Lévêque

Pessac, France

Hopital Purpan

Toulouse, France

Chru de Nancy- Hopital de Brabois

Vandœuvre-lès-Nancy, France

Azienda Ospedaliero-Universitaria Orsola-Malpighi - Universita Degli Studi Di Bologna

Bologna, Italy

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia (Presidio Montichiari)

Brescia, Italy

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori

Meldola, Italy

Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico

Milan, Italy

Ospedale San Raffaele

Milan, Italy

Azienda Ospedaliera Universitaria Federico Ii

Naples, Italy

Azienda Ospedale Universita Di Padova

Padova, Italy

Fondazione Policlinico Universitario Agostino Gemelli Irccs

Roma, Italy

Amsterdam Umc, Locatie Vumc

Amsterdam, Netherlands

Radboudumc

Nijmegen, Netherlands

Erasmus Medisch Centrum

Rotterdam, Netherlands

University Medical Center Utrecht

Utrecht, Netherlands

Ico Badalona. Hospital Universitario Germans Trias I Pujol

Badalona, Spain

Hospital Universitario La Paz

Madrid, Spain

Castle Hill Hospital

Cottingham, United Kingdom

Barts Hospital

London, United Kingdom

Plymouth Hospitals Nhs Trust

Plymouth, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07104565

Related Trials

A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag

NCT075877231 location

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT0700796236 locations

Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

NCT076577931 location

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

NCT048004581 location

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

NCT072067581 location